Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, may lead to gastroesophageal varices. The quality of life, morbidity, and mortality of MPN patients mainly depend on disease-related symptoms, thromboembolic and hemorrhagic complications. Previous studies have shown that JAK2 V617F has a prominent role in vascular risk and MPN-associated gastroesophageal varices. The aim of this study is to evaluate the efficacy of anticoagulation in patients with JAK2 mutation and gastroesophageal varices.
Name: Anticoagulation Agents
Description: The changes of portal vein thrombosis including progression, disappear or unchanged.
Measure: Changes of portal vein thrombosis Time: 1 yearDescription: The occurrence of variceal bleeding including haematemesis and melena
Measure: The occurrence of variceal bleeding Time: 1 yearDescription: Overall survival rate
Measure: Overall survival Time: 1 yearCase-Control
There is one SNP
Previous studies have shown that JAK2 V617F has a prominent role in vascular risk and MPN-associated gastroesophageal varices. --- V617F ---